Fig. 1
Workflow for establishing an orthotopic bioluminescent mouse model of radiorecurrent prostate cancer. (A) Luc2-expressing PAR and CF cells are plated in a 96-well plate with luciferin at linearly increasing densities, and bioluminescent signal intensity is measured. (B) Bioluminescent signals of PAR and CF cells are quantified and fit to a simple linear regression model (PAR: r2 = 0.99, P = 0.0004; CF: r2 = 0.9813, P = 0.0011). Means, standard deviations, and statistical significance of biological replicates are shown. (C) To orthotopically implant cells into the prostates of athymic nude mice, a midline abdominal incision was made, revealing the seminal vesicles (SV) and bladder (B). (D) The seminal vesicles were gently retracted to expose the dorsal prostate lobes (P), contoured in white. (E) Cells were injected bilaterally into each lobe of the prostate via needle (parallel to yellow arrow). (F) After orthotopic injection, mice were administered 150 mg/kg of luciferin and placed in the Newton FT500 imager to monitor in vivo tumour growth with BLI.
